From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook

Unsubscribe

Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets)

From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook

Written by Leo Miller on May 20, 2026 

GLP-1 weight-loss medication bottle and capsules on a desk with glasses and notebook, illustrating the expanding obesity drug market.

Key Points

  • Eli Lilly saw a huge gain after its recent earnings report, but the wins didn’t stop there
  • Lilly also recently got a boost after releasing strong results for its oral GLP-1, Foundayo
  • The data provides evidence that Foundayo is effective in helping keep lost weight off, supporting an emerging growth vertical for Lilly
  • Special Report: The SpaceX IPO has a hidden side that Wall Street isn’t discussing (From Brownstone Research)

Shares of Eli Lilly and Company (NYSE: LLY), the world’s most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%. However, the stock has rebounded mightily since then.

Lilly’s highly impressive earnings reportkicked off the rally, with shares surging nearly 10% in one day. Lilly has continued to trudge higher, now down only around 5% in 2026.

One event that recently helped Lilly’s stock move up was the latest results surrounding its oral GLP-1 medication Foundayo. While Foundayo is already approved by the Food and Drug Administration, the need to continue testing does not stop there. By generating more robust and a wider variety of data on the medication, Lilly can improve the chances of doctors prescribing it. Lilly’s latest results support this all-important goal.

Your book attached (Ad)

Your Download Link (Expiring)

If you still haven’t downloaded the free Simple Options Trading For Beginners guide…please take a few seconds and download it right now before your download link expires. 

That way, no matter what it costs in the future, you’ll have a free copy on your computer.Simple Options Trading For Beginners (Download Link Expires)…

Foundayo’s 2-Pronged Attack: Needle Fear Patients and Maintenance Patients

The trial in question focuses on weight-loss maintenance—helping patients keep lost weight off after they stop taking high-dose GLP-1s. For Lilly, this is part of a two-pronged strategy to generate demand for Foundayo.

The first part is based on attracting completely new patients. Researchers estimate that up to 25% of U.S. adults have a fear of needles, preventing certain patients who want to lose weight from taking injectable GLP-1s. Through pill-based medications, Lilly can unlock demand from this patient group.

However, Lilly is falling behind Novo Nordisk A/S (NYSE: NVO) on oral uptake, as Novo received approval for its oral weight-loss drug several months earlier. Novo’s pill has also demonstrated efficacy that moderately surpasses Foundayo. Novo notes an average weight loss of 14% after 64 weeks among patients taking the Wegovy pill. This compares to an average weight loss of 12.4% after 72 weeks for Foundayo.

According to BMO Capital Markets, “While Foundayo scripts have been trending upward since launch in April, scripts have lagged vs. those of the Wegovy Pill and Street expectations.”

However, Lilly may be able to better differentiate itself in the second prong of its strategy: weight loss maintenance. Injectables are more efficacious than either pill, with Lilly touting an average weight loss of 20.2% at 72 weeks for patients using Zepbound. Thus, after losing a lot of weight on injectables, patients can transition to pills in order to keep lost weight off.

With this, Lilly can drive recurring sales of Foundayo as patients make the switch. Its latest Foundayo results provided encouraging data on this front.

Foundayo: Weight Loss Maintenance Improves Dramatically Versus Going Cold Turkey

In its ATTAIN-MAINTAIN trial, Lilly looked at patients who had lost significant weight through taking Zepbound. Throughout the Zepbound period, patients lost an average of 55 lbs. Patients then transitioned onto Foundayo for 52 weeks, gaining back 11 lbs. So, when using Foundayo as a maintenance treatment, patients regained only 20% of their original weight loss.

This is actually a strong showing, as patients who get off GLP-1s completely regain much more weight. A recent analysis of 48 studies found that after one year of getting off GLP-1s, patients regained 60% of their original weight loss. Thus, the percentage of weight loss kept in Lilly’s study is three times higher than that of those who got off GLP-1s completely.

Lilly also performed the same test with patients who originally lost 41 lbs by taking injectable Wegovy. After switching to Foundayo for 52 weeks, these patients regained just 2 lbs—another very strong result. In the end, Zepbound to Foundayo patients lost 17.2% of their weight, and Wegovy to Foundayo patients lost 15.5% of their weight on average.

Clearly, these results provide evidence that transitioning to Foundayo after taking injectables can be an effective pathway for keeping lost weight off. Notably, on the day of this data release, Lilly’s shares rose by 2.4%.

There is also reason to believe that Foundayo will have greater appeal as a weight-loss maintenance treatment than the Wegovy pill. This is because it comes with no dietary restrictions. Meanwhile, doctors advise Wegovy pill patients not to eat or drink for 30 minutes after taking the medication.

Ultimately, the convenience factor of pills is a key reason why people would want to switch from injectables. With no dietary restrictions, Lilly has an advantage here. However, it will be interesting to see if Novo conducts a similar maintenance study that could shift the playing field in this vertical.

The #1 stock to buy BEFORE the June S-1 filing (Ad)

When the SpaceX IPO launches, most retail investors will be locked out. The banks, funds, and insiders get in early – while everyone else waits on the sidelines.

But one small infrastructure supplier – a critical piece Musk can’t scale the Colossus network without – is still trading well under institutional radar. A new briefing reveals the name and ticker at no cost.Get the SpaceX infrastructure stock name and ticker here

Analysts Forecast Substantial Upside in Lilly After Recent Rebound

Overall, targeting the weight-loss maintenance market is one of many levers Eli Lilly can pull to continue growing its GLP-1 business. Notably, even with Lilly only down less than 10% from its all-time high, Wall Street analysts continue to forecast substantial gains ahead. The MarketBeat consensus price target on the stock sits near $1,218, implying upside of just over 20%.

Read this article online ›

Featured Articles

MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market.

Did you like this article?

I liked this article.
I did not like this article.

Thank you for subscribing to TickerReport, where we work around-the-clock 
to bring you the latest market-moving news.

Contact Us  |  Unsubscribe

© 2006-2026 MarketBeat Media, LLC dba TickerReport. All rights protected.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103. United States of America..

Unknown's avatar

Published by RJ Hamster

I was born on 6 August 1956 in San Francisco, California to Janet and (the late) Richard Hovis. I grew up in Santa Monica, California where I attended elementary, junior high school, and high school (graduating in 1974), in addition to involvement in sports and recreation (Little League +, the Boy’s Club ++). Further, it was in elementary school – St. Augustine’s By-the -Sea Parish School that I found, and made the choice to truly journey with God. I attended Arizona State University from 1974 to 1977 – seeking to become an architect, however, I was not accepted, and, as such, I graduated with a Liberal Arts degree. Upon graduation from Arizona State University, I attended Cal Poly San Luis Obispo and studied City and Regional Planning at the Master’s level. I successfully completed one (1) year in a two (2) year program – I did not complete the Master’s degree in City and Regional Planning – due to personal reasons. I returned to Santa Monica where I started (October 1979) my career as graphic designer with Exxon Company, USA. I spent five years with Exxon Company, USA. While working with Exxon Company, USA I was accepted into architectural school – Sci-Arc in Southern California, however, I did not attend preferring to stay with Exxon.. In 1982 I married Laura Flosi and in April 1983 we had our one and only child – Lauren Alain Hovis – a gift from God. We moved to Phoenix, Arizona in 1984 from Los Angeles, where I went to work as a graphic designer with Kitchell CEM (from 1985 -1987). From 1987 – 1995 I was an independent contractor, and a registered representative in mortgage finance, financial management, graphic design, and drafting. Further, I attended the University of Phoenix and successfully obtained a Master’s in Business Administration (MBA) in 1982. I was also a member of the Scottsdale Jaycees, where I became very involved in community events and projects. In 1994, I accepted a cartography position with the Defense Mapping Agency in Reston, Virginia. As such, I relocated from Phoenix to Reston. In 1998, I was accepted and worked as a Visual Information Officer with the Central Intelligence Agency. In 2002, I worked as a Support Officer until my retirement (due to a need for shoulder surgery) in September 2018. Away from my Federal Government service, I have been involved in various organizations and activities in Northern Virginia. In November of 2011, I married Rebecca Ouellette in Santa Monica, California. I reside in San Tan Valley, AZ with my two hamster - Jess and Timothy, our fish, our lizard - RJ Lizard., and our cats - Pearl and Grey. As to hobbies, I enjoy playing sports, attending sporting events, mentoring individuals from financial management to hamsters, building models, photography, travel, multimedia design, managing partner for RJ Hamster, and jazz – smooth jazz to a samba or a bossa nova. Love and God Bless, Peter – aka RJ Hamster Jo hi

Leave a Comment